Clinical trial / 2017
Combined chondroitin sulfate and glucosamine sulfate was not superior to placebo for knee osteoarthritis pain or functional impairment over 6 months.
A 6-month trial evaluated oral chondroitin sulfate (1,200 mg) plus glucosamine sulfate (1,500 mg) daily versus placebo in 164 patients with symptomatic knee osteoarthritis. In the modified intent-to-treat population, combination therapy was inferior to placebo for joint pain reduction (mean ± SEM change in VAS pain -11.8 ± 2.4 mm [19%] vs. -20.5 ± 2.4 mm [33%], between-group difference 8.7 mm, P < 0.03), though no difference was seen in per-protocol completers. Total WOMAC scores, WOMAC pain and function subscales, OMERACT-OARSI response rates, and rescue medication use did not differ between groups. Severe adverse events were uncommon and distributed equally.
- Study type
- Multicenter, randomized, double-blind, placebo-controlled trial
- Who was studied
- 164 patients with Kellgren/Lawrence grade 2 or 3 radiographic knee osteoarthritis and moderate-to-severe knee pain
- What was measured
- Change from baseline in VAS global pain score, WOMAC scores, OMERACT-OARSI responder rates, and rescue medication use
THE PAPER
Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, Largo R, Herrero-Beaumont G, CS/GS Combined Therapy Study Group. Arthritis Rheumatol, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.